A Response to: Letter to the Editor Regarding “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s C
A Response to: Letter to the Editor Regarding "Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain"
Authors
- Julia Llinares
- Olivia Ashman
- David Carcedo
- Cristina Encinas
- Patrick Halavacek
- Joaquín Martínez-López
- Virginia Lozano
Institutions
- Pfizer (United States) (US)
- Saint Louis University (ES)
- Pfizer (United Kingdom) (GB)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hygeia Hospital (GR)
- Pfizer (Spain) (ES)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1007/s40487-026-00421-2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00